When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

Always speak with your doctor before starting any new supplement or exercise ... keeping you on track even after you’re done ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ... “This update is a result of our significant investment in capacity ...

Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

The Ro Body Program offers eligible individuals access to Wegovy, as well as Ozempic and Zepbound, after consulting ... it for several months before you start seeing results.

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.People who r ...

Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy, will probably become ...

German medical technology company Siemens Healthineers reported a full-year adjusted earnings before interest and taxes (EBIT) and revenue growth in line with analysts' consensus on Wednesday.

In a statement, Novo Nordisk said all doses of Wegovy and Ozempic are being shipped regularly to wholesalers. The Danish drugmaker said the FDA's update is a result ... a week after Novo Nordisk ...